Hematologic Malignancies

Area of TherapyPreclinicalPhase IPhase IIPhase III
Multiple Myeloma (relapsed/refractory) | BOSTON

Rights : Drug: selinexor

Preclinical
Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma DLBCL (relapsed/refractory) | SADAL

Rights : Drug: selinexor

Preclinical
Phase I
Phase II
Phase III
Multiple Myeloma (relapsed/refractory and front-line) | STOMP

Rights : Drug: selinexor

Preclinical
Phase I
Phase II
Phase III
Multiple Myeloma (penta-refractory) | STORM

Rights : XPOVIO (selinexor) is approved in the U.S. in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

Approved

Solid Tumor Malignancies

Area of TherapyPreclinicalPhase IPhase IIPhase III
Liposarcoma | SEAL

Rights : Drug: selinexor

Preclinical
Phase I
Phase II
Phase III
Endometrial Cancer | SIENDO

Rights : Drug: selinexor

Preclinical
Phase I
Phase II
Phase III
Glioblastoma | KING

Rights : Drug: selinexor

Preclinical
Phase I
Phase II
Phase III

Additional Onocology Programs

Area of TherapyPreclinicalPhase IPhase IIPhase III
Myelodysplastic Syndromes (MDS), Colorectal Cancer (CRC) and Prostate Cancer (PrC)

Rights : Drug: eltanexor

Preclinical
Phase I
Phase II
Phase III
Solid Tumors & Lymphoma

Rights : Drug: KPT-9274

Preclinical
Phase I
Phase II
Phase III

Other Indications

Area of TherapyPreclinicalPhase IPhase IIPhase III
Lymphoma in Companion Animals

Rights : Drug: verdinexor

Preclinical
Phase I
Phase II
Phase III

Partnerships

Ono licensed rights to selinexor and eltanexor in the following territories: Japan, S. Korea, Taiwan, Hong Kong, and ASEAN Countries 


antegene-logo

Antegene licensed rights to selinexor and eltanexor in China and Macau

Antengene licensed rights to KPT-9274 and verdinexor in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries


Anivive holds exclusive worldwide rights to research, develop, and commercialize verdinexor only for the treatment of cancer in companion animals